The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

No abstract is available for this paper.

• Publication year

  2000

• Venue

  American Journal of Gastroenterology

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1572-0241.2000.03210.xPMID 11095353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

  1999cited by this paper
• Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

  1999influential reference
• Slow-release lanreotide treatment in endocrine gastrointestinal tumors

  1998cited by this paper
• High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.

  1997cited by this paper
• Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.

  1996cited by this paper
• Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.

  1996cited by this paper
• Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

  1996cited by this paper
• Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group

  1996cited by this paper
• Recent advances in the treatment of metastatic pancreatic endocrine tumors.

  1995cited by this paper
• Clinical review 72: diagnosis and management of functioning islet cell tumors.

  1995cited by this paper
• Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

  1993cited by this paper
• Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

  1992cited by this paper
• Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro.

  1992cited by this paper
• Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut

  1989cited by this paper
• In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue.

  1988cited by this paper
• Karnofsky memorial lecture. An odyssey in the land of small tumors.

  1987cited by this paper
• Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

  1986cited by this paper
• Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.

  1983cited by this paper

• From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms

  2024cites this paper
• The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives

  2024cites this paper
• Conventional Transarterial Chemo embolization Using Streptozocin in Patients with Unresectable Neuroendocrine Liver Metastases

  2023cites this paper
• Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

  2023cites this paper
• The Role of Receptor–Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors

  2023cites this paper
• Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

  2022cites this paper
• Sex differences in carcinoid syndrome: A gap to be closed

  2022cites this paper
• Bronchial Carcinoids: From Molecular Background to Treatment Approach

  2022cites this paper
• Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

  2022cites this paper
• Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

  2021cites this paper
• A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review

  2021cites this paper
• Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review

  2021cites this paper
• 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans

  2021cites this paper
• Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology.

  2020cites this paper
• Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.

  2020cites this paper
• Oncological management of advanced neuroendocrine tumours (Review).

  2020cites this paper
• MEDICAL MANAGEMENT OF GEPNETS

  2020cites this paper
• Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms

  2019cites this paper
• Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future

  2019cites this paper
• Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group.

  2019cites this paper
• Carcinoid Tumours of the Gastrointestinal System: Neuroendocrine Tumours of the Hindgut

  2018cites this paper
• Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines

  2018cites this paper
• Pancreatic Neuroendocrine Tumors Therapy

  2018cites this paper
• Current best practice in the management of neuroendocrine tumors

  2018cites this paper
• Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.

  2018cites this paper
• Therapy for Metastatic Disease: Bronchi

  2018cites this paper
• The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.

  2017cites this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cites this paper
• Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

  2017cites this paper
• Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report

  2017cites this paper
• Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract

  2017cites this paper
• Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?

  2017cites this paper
• Erratum to: Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

  2017cites this paper
• Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

  2016cites this paper
• Development of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactions

  2016cites this paper
• Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors

  2016cites this paper
• Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

  2016cites this paper
• Neuroendocrine tumours - Medical therapy: Biological.

  2016cites this paper
• Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study

  2016cites this paper
• Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules

  2016cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2016cites this paper
• Nonfunctioning Pancreatic Neuroendocrine Tumors

  2015cites this paper
• Interventional radiology: role in the treatment of liver metastases from GEP-NETs

  2015cites this paper
• Neuroendocrine tumors of the colon and rectum

  2015cites this paper
• Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

  2015cites this paper
• Somatostatin Analogues and Radionuclides Used in Therapy

  2015cites this paper
• Biotherapy for neuroendocrine tumours

  2015cites this paper
• The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors

  2015cites this paper
• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

  2015cites this paper
• Systemic therapy for pulmonary carcinoids.

  2015cites this paper
• Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors

  2015cites this paper
• Profile of lanreotide autogel and its potential in the treatment of gastroenteropancreatic neuroendocrine tumors

  2015cites this paper
• Somatostatin Analogs and Interferon in the Treatment of Neuroendocrine Tumors

  2015cites this paper
• Computational protein design: assessment and applications

  2015cites this paper
• SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors: A Comprehensive Multidisciplinary Team Approach

  2015cites this paper
• An update on gastroenteropancreatic neuroendocrine tumors.

  2014cites this paper
• Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.

  2014cites this paper
• Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.

  2014cites this paper
• GEP-NETs update: Biotherapy for neuroendocrine tumours.

  2014cites this paper
• An esophageal neuroendocrine tumor metastatic to the pineal region

  2014cites this paper
• Somatostatin analogs: does pharmacology impact antitumor efficacy?

  2014cites this paper
• Optimisation of Neuroendocrine Tumor Treatment : Locoregional administration, combination therapy and multimodal imaging

  2014cites this paper
• Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

  2013cites this paper
• Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives

  2013cites this paper
• Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors

  2013cites this paper
• A Case of a Pancreatic Tumor Producing Somatostatin with Liver Metastasis Two and 22 Years after Initial Resection

  2013cites this paper
• Systemic therapeutic options for carcinoid.

  2013cites this paper
• n euroendocrine t umors: Role of Imaging in Diagnosis and Management 1

  2013cites this paper
• Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas

  2013cites this paper
• Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management.

  2013cites this paper
• Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence

  2013cites this paper
• Islet Cell Tumors

  2013cites this paper
• Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

  2013cites this paper
• Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes

  2013cites this paper
• Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy

  2012cites this paper
• Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.

  2012cites this paper
• Quality of Clinical Trials in Gastroenteropancreatic Neuroendocrine Tumours

  2012cites this paper
• The expanding role of somatostatin analogs in the management of neuroendocrine tumors.

  2012cites this paper
• Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional

  2012cites this paper
• Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

  2012cites this paper
• A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases

  2012cites this paper
• Supported oligomethionine sulfoxide and Ellman’s reagent for cysteine bridges formation

  2012cites this paper
• Antitumor effects of somatostatin analogs in neuroendocrine tumors.

  2012cites this paper
• Targeted radiotherapy with radiolabeled somatostatin analogs.

  2011cites this paper
• Neuroendocrine tumors: current recommendations for diagnosis and surgical management.

  2011cites this paper
• Medizinische Therapie und Chemotherapie von neuroendokrinen Tumoren

  2011cites this paper
• Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate

  2011cites this paper
• Oxyfold: a simple and efficient solid-supported reagent for disulfide bond formation.

  2011cites this paper
• A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.

  2011cites this paper
• Somatostatin analogs for the treatment of neuroendocrine tumors

  2011influential citation
• Management of Metastatic Carcinoid Tumors

  2011cites this paper
• Ghrelin in neuroendocrine tumors.

  2011cites this paper
• The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel

  2011cites this paper
• Medical Management of Islet Cell Carcinoma

  2011cites this paper
• Neuroendocrine Tumors: A Critical Appraisal of Management Strategies

  2010cites this paper
• Role of somatostatin analogs in the management of neuroendocrine tumors.

  2010cites this paper
• 9. Pharmacological Therapy of Neuroendocrine Tumors

  2010cites this paper
• Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

  2010cites this paper
• Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)

  2010cites this paper
• Antitumour Effects of Somatostatin Analogues in the Treatment of Neuroendocrine Tumours

  2010cites this paper